The delta variant of SARS-CoV-2, the virus that causes COVID-19, has been making headlines as it has quickly become the most prevalent strain in America. But other variants of the virus are still out ...
Prior COVID-19 vaccination did not stop the immune system from mounting a protective response to the delta and omicron strains, though new mutation-specific antibody production dipped slightly, ...
CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...
Vir Biotechnology, Inc. (VIR) has already been able to initiate its late-stage ECLIPSE program, which is using the combination of monoclonal antibody tobevibart in combination with small interfering ...